lifesciencesipreview21h
Natera loses $96m jury win as judge invalidates DNA test patents
Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...
Guardant Health price target raised to $50 from $34 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health (GH) to $50 from $34 following quarterly results. The ...
Piper Sandler Keeps Their Buy Rating on Guardant Health (GH)
In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Guardant Health (GH – Research Report), with a price ...
Hosted on MSN22h
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Guardant Health (GH) one of those stocks right now? By taking ...